Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Risk Stratification Research Critical To Improving Efficiency - Avalere

This article was originally published in The Gray Sheet

Executive Summary

Risk stratification guidelines will be a valuable tool for reducing the cost and improving the quality of cardiovascular care, according to researchers for Washington, D.C.-based consultancy Avalere Health

You may also be interested in...



AHRQ: Two Devices Could Help Diagnose Heart Disease, But Need More Data

While coronary angiography remains the gold standard for diagnosing coronary artery disease, non-invasive tests such as Heartscape Technologies' Prime ECG and Premier Heart's 3DMP show potential.

AHRQ: Two Devices Could Help Diagnose Heart Disease, But Need More Data

While coronary angiography remains the gold standard for diagnosing coronary artery disease, non-invasive tests like Heartscape Technologies' Prime ECG and Premier Heart's 3DMP show potential, according to a 1report from the Agency for Healthcare Research and Quality

AHRQ: Two Devices Could Help Diagnose Heart Disease, But Need More Data

While coronary angiography remains the gold standard for diagnosing coronary artery disease, non-invasive tests like Heartscape Technologies' Prime ECG and Premier Heart's 3DMP show potential, according to a 1report from the Agency for Healthcare Research and Quality

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027639

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel